[en] [en] OBJECTIVES: Our objective was to evaluate the efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in a real-world setting in Belgium.
METHODS: This was a retrospective, multicentre cohort study involving adult treatment-naïve (TN) and treatment-experienced (TE) people living with HIV receiving BIC/FTC/TAF between 1 January 2019 and 30 September 2020. The primary outcome was rate of virological suppression (plasma HIV-1 viral load <50 copies/mL; on-treatment analysis) at weeks 24 and 48. The main secondary outcomes included loss of virological suppression (LVS; two consecutive viral loads of >200 copies/mL after being virologically suppressed) by week 48 and analysis of resistance-associated mutations at time of LVS; tolerability of BIC/FTC/TAF over the 48-week study period; and change in weight and proportion of participants reporting a >10% weight gain at week 48.
RESULTS: Overall, 2001 participants were included. Through 48 weeks, overall rate of virological suppression was 93.5%, with similar results observed in the following subgroups: age ≥50 years (92.7%), women (92.8%), Black sub-Saharan African (91%), TN (94%), TE (93.2%), and non-suppressed at baseline (86.6%). LVS was observed in 0.7% (n = 14) of participants, with one participant developing resistance-associated mutations to nucleoside reverse transcriptase inhibitors (184 V) and integrase strand transfer inhibitors (263KR). Of the 131 (6.5%) treatment discontinuations, the most common reason was an adverse event (2.4%), with the most frequent being central nervous system/psychiatric (0.4%) and gastrointestinal (0.4%) toxicity. Median weight gain at week 48 was 2 kg (interquartile range -1 to 5), and a >10% weight increase was observed in 11.6% of participants.
CONCLUSION: In this large real-world cohort, BIC/FTC/TAF showed excellent virological efficacy in a diverse population of patients with HIV. Rare occurrence of emergent drug resistance was observed, and treatment was well tolerated.
Disciplines :
Immunology & infectious disease
Author, co-author :
Nasreddine, Rakan ; Saint-Pierre University Hospital, Brussels, Belgium
Florence, Eric; Institute of Tropical Medicine, Antwerp, Belgium
Yombi, Jean Cyr; Cliniques Universitaires Saint-Luc, Brussels, Belgium
Henrard, Sophie; University Clinics of Brussels - Erasme Hospital, Brussels, Belgium
Darcis, Gilles ; Centre Hospitalier Universitaire de Liège - CHU > > Service des maladies infectieuses - médecine interne
Van Praet, Jens ; AZ Sint-Jan Brugge-Oostende, Brugge, Belgium
Vandekerckhove, Linos; Ghent University Hospital, Ghent, Belgium
U.S. Department of Health and Human Services. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Available at: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdol escentGL.pdf. Accessed September 5, 2022
European AIDS Clinical Society. European guidelines for clinical management and treatment of HIV-1-infected adults in Europe, version 11, 2021. Available at: https://www.eacsociety.org/ media/final2021eacsguidelinesv11.0_oct2021.pdf. Accessed September 5, 2022
Saag MS, Gandhi RT, Hoy JF, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the international antiviral society-USA panel. JAMA. 2020;324:1651-1669.
World Health Organization. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV. HIV Treatment-Interim Guidance, 2018 Available at: http://apps.who.int/iris/bitstream/handle/ 10665/273632/WHO-CDS-HIV-18.18-eng.pdf?ua=1. Accessed September 5, 2022
Sax PE, DeJesus E, Crofoot G, et al. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial. Lancet HIV. 2017;4:e154-e160.
Gallant J, Lazzarin A, Mills A, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017;390:2063-2072.
Sax PE, Pozniak A, Montes ML, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet. 2017;390:2073-2082.
Stellbrink HJ, Arribas JR, Stephens JL, et al. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, noninferiority trial. Lancet HIV. 2019;6:e364-e372.
Wohl DA, Yazdanpanah Y, Baumgarten A, et al. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2019;6:e355-e363.
Molina JM, Ward D, Brar I, et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet HIV. 2018;5:e357-e365.
Daar ES, DeJesus E, Ruane P, et al. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2018;5:e347-e356.
Sax PE, Rockstroh JK, Luetkemeyer AF, et al. Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with human immunodeficiency virus. Clin Infect Dis. 2021;73:e485-e493.
Parienti J, Barrail-Tran A, Duval X, et al. Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial. Antimicrob Agents Chemother. 2013;57(5):2265-2271.
Sciensano. Epidémiologie du sida et de l'infection à VIH en Belgique: situation au 31 décembre 2020. Available at: https://www.sciensano.be/en/biblio/epidemiologie-du-sida-et-de-linfection-a-vih-en-belgique-situation-au-31-decembre-2020. Accessed September 9, 2022
United Nations Statistics Division. Composition of macro geographical (continental) regions, geographical sub-regions, and selected economic other groupings. Available at: https://unstats.un.org/unsd/mi/africa.htm. Accessed September 9, 2022
Andreatta K, Willkom M, Martin R, et al. Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I. J Antimicrob Chemother. 2019;74:3555-3564.
Acosta RK, Willkom M, Andreatta K, et al. Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) from dolutegravir (DTG)+F/TAF or DTG+F/tenofovir disoproxil fumarate (TDF) in the presence of pre-existing NRTI resistance. J Acquir Immune Defic Syndr. 2020;85:363-371.
Andreatta K, D'Antoni ML, Chang S, et al. Preexisting resistant and week 48 virologic outcomes after switching to B/F/TAF in african american adults with HIV. Open Forum Infect Dis. 2020;7(Suppl 1):S183-S184.
Chamberlain N, Brock JB, Meena LA. BIC/FTC/TAF maintains viral suppression in patients with documented M184V/I mutations: a real world experience. Open Forum Infect Dis. 2020;7(Suppl 1):S530.
Wohl DA, Pozniak A, Workowski K, et al. B/F/TAF five-year outcomes in treatment-naive adults. [Abstract 494] 29th Conference on Retroviruses and Opportunistic Infections (CROI) 12–16 February 2022.
Kityo C, Hagins D, Koenig E, et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) in virologically suppressed HIV-1 infected women: a randomized, open-label, multicenter, active-controlled, phase 3, noninferiority trial. J Acquir Immune Defic Syndr. 2019;82:321-328.
Ambrosioni J, Liévano JR, Berrocal L, et al. Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical Centre. J Antimicrob Chemother. 2022;77(4):1133-1139.
Micán R, de Gea GA, Busca C, et al. Efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in patients with pre-existing NRTI resistances: Real world data. [Abstract 96] 18th European AIDS Conference (EACS) 27–30 October 2021.
Rolle C-P, Nguyen V, Patel K, Cruz D, DeJesus E, Hinestrosa F. Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV. Medicine. 2021;100(38):e27330.
Spinner CD, Stoehr A, Wong A, et al. Starting or switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in clinical practice: Pooled 12-month results from the global BICSTaR study. [Abstract 46] HIV Drug Therapy 5–8 October 2020.
Gunn JKL, Patterson W, Anderson BJ, Swain C-A. Understanding the risk of human immunodeficiency virus (HIV) virologic failure in the era of undetectable equals untransmittable. AIDS Behav. 2021;25(7):2259-2265.
Braun P, Wiesmann F, Naeth G, Knechten H, Stoll M. Development of integrase inhibitor resistance under firstline treatment with Bictegravir. [Abstract 125] HIV Drug Therapy 5–8 October 2022.
Chamberlain N, Mena L, Brock JB. Case report: emergent resistance in a treatment-naive person with human immunodeficiency virus under bictegravir-based therapy. Open forum Infect Dis. 2021;8(6):ofab297.
Dauny V, Gras E, Levi L, et al. Identification of a treatment-emergent integrase resistance mutation in an HIV late-presenter on first-line therapy. [Abstract 209] 18th European AIDS Conference (EACS) 27–30 October 2021.
Garcia-Gasco P, Maida I, Blanco F, et al. Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome. J Antimicrob Chemother. 2008;61(3):699-704.
Cohen Stuart JW, Wensing AM, Kovacs C, et al. Transient relapses (“blips”) of plasma HIV RNA levels during HAART are associated with drug resistance. J Acquir Immune Defic Syndr. 2001;28(2):105-113.
Grennan JT, Loutfy MR, Su D, et al. Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. J Infect Dis. 2012;205(8):1230-1238.
Goldberg RN, Kania AT, Michienzi SM, Patel M, Badowski ME. Weight gain in incarcerated individuals living with HIV after switching to integrase strand inhibitor-based therapy. J Int Assoc Provid AIDS Care. 2021;20:2325958221996860.
Taramasso L, Berruti M, Briano F, Di Biagio A. The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen. AIDS. 2020;34(6):877-881.
Sax PE, Erlandson KM, Lake JE, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. 2020;71(6):1379-1389.
Eckard AR, McComsey GA. Weight gain and integrase inhibitors. Curr Opin Infect Dis. 2020;33:10-19.
Emond B, Rossi C, Côté-Sergent A, et al. Weight change and predictors of weight change among patients initiated on darunavir/cobicistat/emtricitabine/ tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide: a real-world retrospective study. J Health Econ Outcomes Res. 2021;8(1):88-98.
Lake JE, Trevillyan J. Impact of integrase inhibitors and tenofovir alafenamide on weight gain in people with HIV. Curr Opin HIV AIDS. 2021;16(3):148-151.
Gomez M, Seybold U, Roider J, Härter G, Bogner JR. A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one german university hospital in 2015–2017. Infection. 2019;47(1):95-102.
Bakal DR, Coelho LE, Luz PM, et al. Obesity following ART initiation is common and influenced by both traditional and HIV−/ART-specific risk factors. J Antimicrob Chemother. 2018;73(8):2177-2185.
Saumoy M, Sanchez-Quesada JL, Ordoñez-Llanos J, Podzamczer D. Do all integrase strand transfer inhibitors have the same lipid profile? Review of randomised controlled trials in naïve and switch scenarios in HIV-infected patients. J Clin Med. 2021;10(16):3456.
Santos JR, Saumoy M, Curran A, et al. The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial. Clin Infect Dis. 2015;61(3):403-408.
